GlassScriptPhysician profile
Hiva Vakil
NPI 1356480172
$2,067.78
in general payments reported to CMS, 2019-2025
22 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $149 · 2021: $198 · 2022: $235 · 2023: $250 · 2024: $390 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $445.60 | 2023-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $409.62 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $192.63 | 2022-2025 | Assure Wcd |
| Abbott Laboratories | $169.71 | 2019-2022 | |
| Amgen INC. | $140.37 | 2019 | |
| Biosense Webster, INC. | $119.04 | 2020 | |
| Astellas Pharma US INC | $93.10 | 2020-2021 | |
| Cardiovascular Systems INC. | $66.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.76 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $50.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.99 | 2022-2023 | Xarelto |
| Atricure, INC. | $41.61 | 2024 | |
| Pfizer INC. | $40.76 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.25 | 2023 | Wainua |
| Actelion Pharmaceuticals US, INC. | $29.79 | 2024 | Uptravi, Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.26 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $20.83 | 2025 | Amvuttra |
| Abiomed | $18.94 | 2023 | Impella |
| Novo Nordisk INC | $17.83 | 2021 | |
| Merck Sharp & Dohme LLC | $17.31 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiva Vakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.